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Summary In this economic evaluation, conducted alongside a randomized,
double-blind clinical trial, economic data were collected from 339 patients with
moderate-persistent asthma randomized to receive twice-daily, double-blind
treatment with budesonide/formoterol 160/4.5 mg in a single inhaler (n ¼ 166) or
fluticasone propionate 250 mg (n ¼ 173) for 12 weeks. The mean number of episode-
free days (EFD) per patient was significantly greater in the budesonide/formoterolee front matter & 2005
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ess: sb@ihe.se (S. Borggroup than the fluticasone group (48.71 compared with 42.34, P ¼ 0:0185). Data on
medication use, visits to healthcare professionals, and hospitalization were pooled
across all six countries and combined with German and Dutch unit cost data to
calculate total healthcare costs. Using German unit costs, budesonide/formoterol
was associated with significantly lower total healthcare costs per patient over the
12-week period compared with fluticasone (h131 compared with h210, P ¼ 0:0043).
Using Dutch unit costs, total healthcare costs were slightly numerically lower in the
budesonide/formoterol group than the fluticasone group (h102 compared with
h104), but the difference did not reach statistical significance. Budesonide/
formoterol in a single inhaler is more effective than a higher microgram dose of
fluticasone alone. It is cost-neutral and may provide cost-savings in some countries.
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Asthma prevalence is high with an estimated 300
million sufferers worldwide,1 imposing a heavy
economic burden on society as a whole. The cost
of asthma has been calculated at h2.74 billion per
year in Germany2 in 1999, and $10.7 billion per year
in the USA3 in 1994. Hospitalization and indirect
costs (loss of productivity due to being unable to
work because of asthma) accounted for substantial
costs in both studies, indicating sub-optimal asthma
control. Patients with better-controlled asthma
have been shown to incur lower costs,4,5 demon-
strating that improving the control of asthma could
reduce the burden of illness for patients, health-
care systems, and society as a whole.6
International guidelines recommend a stepwise
approach to asthma treatment, titrating mainte-
nance treatment down to the lowest effective
dose.7 Inhaled corticosteroids are recommended
for all but mild-intermittent asthma, with the
addition of a long-acting b2-agonist in patients with
persistent asthma who are not adequately con-
trolled on inhaled corticosteroids alone.7 Clinical
trials have shown that the addition of the long-
acting b2-agonist formoterol to inhaled corticoster-
oid treatment provides better lung function, better
symptom control, and a reduced risk of exacerba-
tions compared with inhaled corticosteroids alone
in patients with moderate-to-severe8 and mild-to-
moderate9 asthma. In addition, using both a long-
acting b2-agonist and an inhaled corticosteroid in a
single inhaler has been shown to improve patient
adherence to medication,10 which in turn can
increase efficacy.11
However, combined therapy has an intrinsically
higher unit cost than inhaled corticosteroids alone.
To address concerns about possible increased costs,
there is a need for economic studies to define the
cost and cost-effectiveness of inhaled corticoster-
oids plus a long-acting b2-agonist compared with
inhaled corticosteroids alone. Such information will
be of help to physicians and budget holders in
deciding on the most appropriate allocation of
resources for treating patients whose asthma is not
fully controlled by inhaled corticosteroids alone.
Economic evaluations have shown that the
addition of formoterol to budesonide maintenance
treatment in separate inhalers can be cost-effec-
tive compared with budesonide alone in patients
with moderate12 and mild13 asthma. As yet, no
studies have investigated the cost-effectiveness of
budesonide/formoterol in a single inhaler com-
pared with inhaled corticosteroids alone.
A clinical trial comparing budesonide/formoterol
in a single inhaler with fluticasone alone demon-strated that budesonide/formoterol significantly
improved lung function, and reduced the number
of exacerbations in patients with moderate asth-
ma.14 An economic analysis was conducted along-
side this study, comparing the cost-effectiveness of
budesonide/formoterol in a single inhaler with
fluticasone alone, and the results are presented
here.Patients and methods
Study design
The clinical study has been described fully else-
where,14 and only brief details are given here. The
study was randomized, double-blind, double-dum-
my, placebo-controlled, and parallel-group and was
conducted at 37 centers in Germany, Greece,
Israel, The Netherlands, Portugal, and South Africa.
Patients were aged X18 years, had a diagnosis of
persistent asthma for X6 months, had been taking
inhaled corticosteroids at a daily dose of
200–1000 mg for X30 days, and had a forced
expiratory volume in 1 s (FEV1) of 60–90% of
predicted normal with at least 12% reversibility
after inhaling 1mg terbutaline or 0.4mg salbuta-
mol. Patients were excluded if they had respiratory
infection, had required oral, parenteral, or rectal
corticosteroids within 30 days of study entry, or had
a history of smoking X10 pack-years.
After a 2-week run-in when they received
budesonide Turbuhalers 200 mg bid (metered
dose), patients were randomized to receive bude-
sonide/formoterol Turbuhalers 160/4.5 mg bid (de-
livered dose) or fluticasone propionate Diskuss
250 mg bid for a further 12 weeks. Placebo devices
were identical in appearance to those containing
active drug. Terbutaline (Bricanyls Turbuhalers) or
salbutamol were available as rescue medications.
Clinical efficacy assessments
The primary clinical efficacy variable was morning
peak expiratory flow (PEF). Secondary variables
included time to first exacerbation, use of rescue
medication, and asthma symptom score. PEF and
asthma symptoms were recorded each morning and
evening using a diary card. Mild and severe
exacerbations were recorded throughout the study.
A mild exacerbation was defined as one of the
following: awakening due to asthma on two con-
secutive nights, morning PEF at least 20% below
baseline value on two consecutive days, or use of at
least four inhalations of reliever medication more
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consecutive days (i.e. over a 48-h period). A severe
exacerbation was defined as: the need for oral
corticosteroids, PEF of at least 30% below baseline
on two consecutive days, or discontinuation due to
asthma worsening.Cost and effectiveness assessments
The primary effectiveness variable used in the
economic analysis was the number of episode-free
days (EFD). An EFD was defined as 24 h without any
asthma symptoms, no use of rescue medication, no
night-time awakening due to asthma, and morning
PEF of at least 80% of baseline. The EFD has been
previously recommended as an economically and
clinically meaningful effectiveness measure that
can be constructed from asthma clinical trial
data.15
The main economic analysis was conducted from
the perspective of a healthcare payer, including
total healthcare costs only. Secondary analyses
were conducted from a societal perspective (also
including productivity costs), and from the per-
spective of a drug budget holder (medication costs
only).
Utilization of healthcare resources and days on
which the patient was unable to work (employment
or home-making) were recorded in the case report
forms.
Use of rescue medication and other asthma
medication was also recorded. Study medication
use was calculated as the intended daily dose
strength multiplied by the intended number of days
in the study (84 days). Study medication use was
thus the same for all patients in a treatment group.
A total of 15 patients in the budesonide/
formoterol group, and 20 in the fluticasone group
discontinued the clinical study before the end of
the 12-week study period; 11 due to disease
deterioration (three in the budesonide/formoterol
group, eight in the fluticasone group), 10 due to
other adverse events (five in each group) and 14 for
other reasons (seven in each group). These dis-
continuations were handled using the patient-year
approach,16 which scales the available data for a
patient to represent the nominal study period of 12
weeks, by imputing the patient’s own observed
average value on each day after discontinuation.
An alternative approach uses group mean imputa-
tion by similarly imputing the treatment group
average on each day after discontinuation, which
gives a greater weight to patients with more days in
the study. A sensitivity analysis was conductedusing this approach to test the effect of the
different calculation methods on the results.
Resource utilization data were pooled across all
six countries. However, different countries may
have different healthcare systems, different treat-
ment patterns, and cultural differences in health-
care use (e.g. differences in when it is thought
appropriate to call a doctor or attend an emer-
gency room), and these may cause different
patterns of resource utilization. The resource use
data in the present study were tested for the
absence of homogeneity using a w2-test on the
number of physician visits, which was the single
most common healthcare contact in the study.
Costs cannot be generalized from one country to
another because differences in the price of
healthcare interventions and medications vary so
greatly between countries. We calculated costs for
Germany and The Netherlands by multiplying the
pooled resource use data by German or Dutch unit
costs, respectively (Table 1). The unit costs were
obtained in 2000 in German Marks (DM) and Dutch
Guilders (NGL), respectively. As these currencies
have now been replaced by the Euro, all costs are
presented in Euros (h1 ¼ DM 1.95583 ¼ NGL
2.20371). These two countries were selected a
priori because they have shown a strong interest in
health economic data, and because unit cost data
for the healthcare resources are readily available.
Calculating costs for two different countries pro-
vides a way of assessing the impact of price
differentials on our findings.
Effectiveness data were compared between
groups using a Wilcoxon rank sum test. Mean values
for cost data were compared using parametric tests
(t-test) based on the central limit theorem.Results
Clinical results
Of the 373 patients enrolled into the study, 344
were randomized. There were 168 patients in the
budesonide/formoterol group (42% male), and 176
patients in the fluticasone group (44% male), with a
mean age of 42.6 years and 41.8 years, respec-
tively. The groups were well balanced at baseline.
The mean duration of asthma was 16.3 years in
both groups; mean pre-study steroid use was
591 mg/day in the budesonide/formoterol group,
and 597 mg/day in the fluticasone group, and mean
pre-study use of reliever medication was 0.9
inhalation/day and 1 inhalation/day, respectively.
Mean FEV1 (% predicted normal) was 77.2 in the
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Table 1 Unit costs in Germany and The Netherlands.
Item Cost in Germany
(DM)
Costs in Germany
(Euros)
Cost in The
Netherlands
(Guilders)
Costs in The
Netherlands
(Euros)
Study medication
Symbicorts Turbuhalers 160/45 mg 1.304/dose17 0.67/dose 1.198/dose18 0.54/dose
Fluticasone (Flixotides) 250 mg 1.697/dose17 0.87/dose 0.654/dose18 0.30/dose
Rescue medication
Bricanyls Turbuhalers (average
dose)
0.09/dose17 0.05/dose 0.19/dose17 0.09/dose
Healthcare resources
Hospitalization (general medicine) 470/day19 240/day 556/day20 252/day
Hospitalization (ICU) 1868/day19 955/day 2536/day20 1151/day
Emergency room 165/visit19 84/visit 91/visit20 41/visit
Physician visit 156/visit21 80/visit 37/visit20 17/visit
House call by physician 49/visit21 25/visit n/a
House call by nurse n/a 71/visit20 32/visit
Phone call to physician 4.0/call21 2.1/call 9.6/call25
Pharmacy visit 10/visit22 5.1/visit 12/visit20 5.5/visit
Productivity costs
1 day absent from work 262/day23 134/day 236/day24 107/day
ICU ¼ intensive care unit; n/a ¼ not available.
Table 2 Clinical efficacy results.
Budesonide/
formoterol
(n ¼ 168)
Fluticasone
(n ¼ 176)
Difference (95% CI) P-value
Change in morning PEFa (l/min) 27.4 7.7 19.7 (13.6, 25.9) o0.001
Change in evening PEFa (l/min) 24.0 6.8 17.2 (11.2, 23.2) o0.001
FEV1
b (l) 2.57 2.46 4.7 (2.0, 7.4) o0.001
Change in reliever medicationa
(inhalations/day)
0.31 0.13 0.18 (0.35, 0.01) 0.04
Patients with one or more mild
exacerbations (%)
29.8 42.0 12.3 (22.2, 2.17) 0.017c
Patients with one or more severe
exacerbations (%)
8 11 — NSc
CI ¼ confidence interval; FEV1 ¼ forced expiratory volume in 1 s; NS ¼ not statistically significant; PEF ¼ peak expiratory flow.
aANOVA adjusting for country and baseline.
bMultiplicative ANOVA, difference expressed as percent.
cBinomial proportions test.
Cost-effectiveness of budesonide/formoterol in moderate asthma 589budesonide/formoterol group and 79.2 in the
fluticasone group.
The clinical efficacy results are summarized in
Table 2. Budesonide/formoterol improved lung
function significantly (Po0:001) more than flutica-
sone, significantly (P ¼ 0:04) reduced the use of
rescue medication, and significantly (P ¼ 0:04)
increased the time to the first mild exacerbation.14Economic results
A total of 339 patients were included in the
economic analysis. This differs from the number
in the clinical analysis (n ¼ 344) as five patients
provided no economic data after randomization.
The mean number of EFD per patient was signifi-
cantly higher in the budesonide/formoterol group
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K. Ericsson et al.590than the fluticasone group (48.71 compared with
42.34, P ¼ 0:0185) (Fig. 1).
Average resource utilization across all six coun-
tries is shown in Table 3.
German healthcare costs are presented in Fig. 2a
and Table 4. Total healthcare costs were signifi-
cantly (Po0:01) lower in the budesonide/formo-
terol group than in the fluticasone group, mainly
due to the lower cost for study medication, rescue
medication, and hospitalization in the budesonide/
formoterol group.
Dutch healthcare costs are presented in Fig. 2b
and Table 4. In The Netherlands, there was no
statistically significant difference in total health-
care costs. Study medication costs were higher in
the budesonide/formoterol group than in the
fluticasone group, but this was fully offset by
reductions in other cost components, mainly
hospitalization and rescue medication. The differ-Table 3 Mean resource utilization per patient over the
Item Budesoni
Rescue medication (inhalations) 48.39
Hospitalization (general medicine) (days) 0
Hospitalization (ICU) (days) 0
Emergency room (visits) 0
Physician visits (n) 0.18
Nurse visits (n) 0.01
House calls (n) 0.01
Phone calls (n) 0.11
Pharmacy contacts (n) 0.13
Time off work (days) 0.26
ICU ¼ intensive care unit.
Time off work:44 h ¼ 1 day, p4 h ¼ 0.5 day. For the unemployed
who stayed home assisting the patient, if applicable.
‘‘Other medication’’ use is the sum of numerous different therapi
cost estimates.
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Figure 1 Mean number of episode-free days per patient
during the study period.ence in study medication costs is due to the larger
difference in price between the two products in
The Netherlands than in Germany (Table 1).
Taking the perspective of a drug budget holder
and looking only at total medication costs, bude-
sonide/formoterol treatment was less costly than
fluticasone treatment in Germany (Table 4). In The
Netherlands, by contrast, total medication cost per
patient over the study period was higher in the
budesonide/formoterol group than in the flutica-
sone group (Table 4). These differences are mainly
the result of the difference in prices for the study
medications in the two countries (Table 1).
In both countries, productivity costs were lower
in the budesonide/formoterol group than in the
fluticasone group (Fig. 3), although the differences
were not statistically significant. Total costs
(healthcare plus productivity costs) were lower in
the budesonide/formoterol group than in the
fluticasone group in both countries (Table 4), but
the difference was only statistically significant in
Germany (P ¼ 0:025).Sensitivity analyses
In the test of homogeneity, it was found that the
pattern of physician visits was not homogeneous.
Israel comprised roughly half of all reported
physician visits, in spite of its relatively low number
of patients (65 out of 339). There was no evidence
of lack of homogeneity when the Israeli patients
were excluded. We therefore conducted a sensi-
tivity analysis to determine whether excluding the
Israeli data influenced the results. The findings
were similar to those of the main analysis (Table 5).study period.
de/formoterol (n ¼ 166) Fluticasone (n ¼ 173)
68.56
0.13
0
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0.21
0
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0.78
, the cost for time off work was only calculated for a person
es and so is not presented here. However, it is included in the
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Figure 2 Mean healthcare costs per patient during the
study period using (a) German and (b) Dutch costs. Some
cost sub-components are too small to be visible in the
figure—see Table 4 for detailed data.
Cost-effectiveness of budesonide/formoterol in moderate asthma 591A further analysis was conducted using the
group mean imputation method to handle early
discontinuations, instead of the patient-year
approach. The findings were similar to those of
the main analysis (Table 5).Discussion
According to international guidelines,7 the goal of
asthma treatment is to achieve maximum asthmacontrol (minimal or no symptoms, minimal or no
lung function impairment, and minimal risk of
exacerbations) and maintain it at the lowest
possible dose of controller treatment, usually
inhaled corticosteroid. Several studies have found
that adding a long-acting b2-agonist to a low or
moderate dose of inhaled corticosteroid provides
more effective asthma control than a higher dose of
inhaled corticosteroid alone.8,9 Guidelines now
recommend that the addition of a long-acting b2-
agonist to inhaled corticosteroid treatment is
preferable to increasing the inhaled corticosteroid
dose in patients with moderate- and severe-
persistent asthma.7 The findings of O’Byrne et al.9
suggest that this might also be a valuable treat-
ment option in patients with mild-to-moderate
asthma who are not fully controlled on inhaled
corticosteroids alone.
The development of single inhaler devices con-
taining both a long-acting b2-agonist, and a
corticosteroid provides a convenient treatment
option for patients who are judged likely to benefit
from combination therapy. Budesonide/formoterol
in a single inhaler (160/4.5 mg bid) was significantly
more effective than fluticasone propionate (250 mg
bid) in improving lung function, reducing the use of
reliever medication, and reducing the risk of mild
exacerbations in patients with moderate-persistent
asthma.14
In addition to clinical evidence, information is
also needed on the economic effects of switching
patients from inhaled corticosteroid monotherapy
to inhaled corticosteroid plus long-acting b2-ago-
nist in a single inhaler. Many patients remain on
monotherapy despite achieving less than optimal
control of symptoms, and in a recent survey only
15% of physicians prescribed an additional drug in
response to worsening asthma symptoms.26 There
may be many reasons for this apparent reluctance
to step up treatment, including misjudgment of the
degree of asthma control achieved,26 concern
about medication (especially corticosteroid) side
effects, and resistance to increasing the complexity
of treatment by adding another inhaler. Concern
over possible increases in healthcare cost may also
be an issue.
The present economic evaluation provides data
that may help physicians and budget holders with a
commonly encountered choice: should a patient
with moderate-persistent asthma not adequately
controlled on inhaled corticosteroids alone receive
a higher microgram dose of inhaled corticosteroid
or inhaled corticosteroid plus a long-acting b2-
agonist?
The present study confirms that budesonide/
formoterol in a single inhaler was more effective
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Table 4 Mean cost per patient over the study period.
Item German costs (Euros) Dutch costs (Euros)
Budesonide/
formoterol
(n ¼ 166)
Fluticasone
(n ¼ 173)
Budesonide/
formoterol
(n ¼ 166)
Fluticasone
(n ¼ 173)
Study medication 112 146 91 50
Rescue medication 2 3 4 6
Other asthma medication 0.2 5 0.2 5
Total medication costs 114 154 96 61
Hospitalization (general medicine) 0 30 0 32
Hospitalization (ICU) 0 0 0 0
Emergency room 0 8 0 4
Physician visits 15 16 3 3
Nurse visitsa 0.5 0 0.1 0
House callsa 0.4 0.5 0.5 0.6
Phone callsa 0.2 0.3 1 1
Pharmacy contacts 0.7 0.6 0.7 0.6
Total healthcare costs, including
medication
131 210 ðP ¼ 0:0043Þ 101 103 (P40:05)
Productivity costs 34 104 ðP40:05Þ 28 83 (P40:05)
Total costs 165 314 ðP ¼ 0:0254Þ 128 186 (P40:05)
ICU ¼ intensive care unit.
Totals may not add exactly due to rounding.
aAggregated as ‘‘other visits and calls’’ in figures.
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Figure 3 Mean productivity costs per patient during the
study period using German and Dutch costs.
K. Ericsson et al.592than fluticasone alone, providing significantly more
EFD per patient. This increase in effectiveness was
achieved at either no increase or a net saving in
healthcare and total costs, depending on the
country. Compared with fluticasone, budesonide/
formoterol was associated with substantially lower
utilization of some resources, such as the mean
number of inhalations of rescue medication (48.39
vs. 68.56), and the mean number of days lost fromwork (0.26 vs. 0.78). Hospitalization and emer-
gency room visits were also lower in the budeso-
nide/formoterol group than the fluticasone group,
but the numbers were small.
Using German unit costs, budesonide/formoterol
was associated with a significant saving in health-
care costs (h80 per patient over the 12-week study
period, P ¼ 0:0043). When productivity costs were
included, thereby taking a societal perspective,
total costs were also significantly lower in the
budesonide/formoterol group than in the fluticasone
group (P ¼ 0:0254). Taking the perspective of a drug
budget holder, and looking only at total medication
costs, budesonide/formoterol treatment was also
less costly than fluticasone treatment (h114 com-
pared with h154), reflecting the fact that Symbi-
corts Turbuhalers 160/4.5mg has a lower
acquisition cost than Flixotides 250mg in Germany.
Thus, using German cost data, formoterol/budeso-
nide in a single inhaler was both more effective and
less costly than fluticasone from all perspectives
analyzed, making it the dominant strategy.
In The Netherlands, the acquisition cost of
fluticasone is lower than that of budesonide/
formoterol, so that the mean cost of study
medication was higher in the budesonide/formo-
terol group than in the fluticasone group. However,
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Table 5 Sensitivity analyses.
Cost item German costs (Euros) Dutch costs (Euros)
Mean costs per patient excluding data from Israel
Budesonide/formoterol Fluticasone Budesonide/formoterol Fluticasone
(n ¼ 135) (n ¼ 139) (n ¼ 135) (n ¼ 139)
Total healthcare costs 127 215 100 110
(P ¼ 0:0095) (P40:05)
Productivity costs 19 101 15 81
(P40:05) (P40:05)
Total costs 146 316 115 191
(P ¼ 0:0325) (P40:05)
Mean costs per patient including data from all six countries and using the group mean imputation approach
Budesonide/formoterol Fluticasone Budesonide/formoterol Fluticasone
(n ¼ 166) (n ¼ 173) (n ¼ 166) (n ¼ 173)
Total healthcare costs 133 195 103 92
(P ¼ 0:0002) (P40:05)
Productivity costs 29 53 24 43
(P40:05) (P40:05)
Total costs 163 249 126 134
(P ¼ 0:0057) (P40:05)
Totals may not add exactly due to rounding.
Cost-effectiveness of budesonide/formoterol in moderate asthma 593this was completely offset by savings in other
medication, and healthcare resource use, so that
total healthcare costs were almost identical in the
two treatment groups. Productivity and total costs
were lower in the budesonide/formoterol group,
but this did not reach statistical significance. Using
Dutch cost data, budesonide/formoterol provided
significantly improved effectiveness with no in-
crease in healthcare or total costs, making it
clearly cost-effective compared with fluticasone
alone.
The pattern of numerically lower costs for use of
healthcare resources and productivity losses ob-
served for the budesonide/formoterol group in both
countries is as would be expected from the
improved asthma control achieved with combined
treatment.
Pooling resource use data from multiple coun-
tries to calculate costs is a methodological issue in
economic studies. Variations in healthcare systems
and treatment patterns may cause problems in
generalizing resource use data across countries.
In the present study, it was found that patients in
Israel were significantly more likely than patients in
other countries to contact a physician. The other
five countries did not show such differences.
Therefore, the results were analyzed with and
without the Israeli data to test the sensitivity of the
results to this inter-country difference. A further
sensitivity analysis was also carried out to test theeffect of using two different approaches to hand-
ling data from patients who discontinued the study
early. Both these analyses showed that the findings
of the study were robust to using these alternative
methodologies.
A limitation of the present study is its short
duration (12 weeks). Asthma is a chronic disease,
and the results from a 12-week period may not
necessarily reflect the effects in long-term treat-
ment. In particular, a study of this length is unlikely
to be able to detect differences in rare (but costly)
events such as hospitalizations. It is possible that
the economic impact of the reduction in the risk of
exacerbations observed in the budesonide/formo-
terol group may have been underestimated.
The findings of the present study are consistent
with other studies investigating the cost-effective-
ness of formoterol plus budesonide in asthma.
Formoterol plus budesonide in separate inhalers
has been shown to be cost-effective compared with
budesonide alone,12,13 and budesonide/formoterol
in a single inhaler has been found to be cost-saving
compared with separate inhaler treatment.27 Other
studies have compared the combination of salme-
terol and fluticasone at various doses with equiva-
lent microgram doses of fluticasone alone, either
by analyzing data collected alongside clinical
studies,28–30 or by Markov computer modeling.31
These have consistently found that the combination
is more effective than fluticasone alone, although
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K. Ericsson et al.594associated with higher or similar total healthcare
costs. However, differences in dose, country-
specific prices, and methodology mean that their
findings may not be directly comparable with those
of the present study.
The present study shows that budesonide/for-
moterol in a single inhaler is more effective than a
higher microgram dose of fluticasone alone. It is
cost-neutral and may provide cost-savings in some
countries. These results indicate that when a
patient is not adequately controlled on inhaled
corticosteroids alone and an additional treatment
step is required, switching to budesonide/formo-
terol in a single inhaler could improve asthma
control without increasing costs, and may even
provide cost savings.References
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